PRESTIGE CONSUMER HEALTHCARE (PBH) Stock Fundamental Analysis
USA - NYSE:PBH - US74112D1019 - Common Stock
63.1 USD
-1 (-1.56%)
63.101 USD
0 (0%)
PBH gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 197 industry peers in the Pharmaceuticals industry. PBH has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PBH is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PBH was profitable.
PBH had a positive operating cash flow in the past year.
Of the past 5 years PBH 4 years were profitable.
PBH had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PBH has a better Return On Assets (6.21%) than 90.36% of its industry peers.
With an excellent Return On Equity value of 11.48%, PBH belongs to the best of the industry, outperforming 87.31% of the companies in the same industry.
PBH has a better Return On Invested Capital (7.95%) than 84.77% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PBH is significantly below the industry average of 15.28%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROIC | 7.95% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
1.3 Margins
With an excellent Profit Margin value of 19.02%, PBH belongs to the best of the industry, outperforming 92.89% of the companies in the same industry.
PBH's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 31.15%, PBH belongs to the top of the industry, outperforming 94.92% of the companies in the same industry.
In the last couple of years the Operating Margin of PBH has remained more or less at the same level.
Looking at the Gross Margin, with a value of 56.13%, PBH is in the better half of the industry, outperforming 64.97% of the companies in the same industry.
PBH's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% |
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PBH is destroying value.
PBH has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PBH has less shares outstanding
The debt/assets ratio for PBH has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.63 indicates that PBH is not a great score, but indicates only limited risk for bankruptcy at the moment.
PBH has a Altman-Z score of 2.63. This is in the better half of the industry: PBH outperforms 70.05% of its industry peers.
The Debt to FCF ratio of PBH is 3.79, which is a good value as it means it would take PBH, 3.79 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.79, PBH belongs to the best of the industry, outperforming 88.32% of the companies in the same industry.
A Debt/Equity ratio of 0.55 indicates that PBH is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.55, PBH is doing worse than 61.93% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Altman-Z | 2.63 |
ROIC/WACC0.85
WACC9.34%
2.3 Liquidity
A Current Ratio of 4.38 indicates that PBH has no problem at all paying its short term obligations.
With a decent Current ratio value of 4.38, PBH is doing good in the industry, outperforming 66.50% of the companies in the same industry.
PBH has a Quick Ratio of 2.99. This indicates that PBH is financially healthy and has no problem in meeting its short term obligations.
PBH has a Quick ratio (2.99) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 14.21% over the past year.
The Earnings Per Share has been growing by 8.88% on average over the past years. This is quite good.
The Revenue has been growing slightly by 0.63% in the past year.
PBH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.39% yearly.
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
3.2 Future
Based on estimates for the next years, PBH will show a small growth in Earnings Per Share. The EPS will grow by 3.32% on average per year.
PBH is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.15% yearly.
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PBH is valuated correctly with a Price/Earnings ratio of 13.78.
PBH's Price/Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 87.82% of the companies in the same industry.
PBH is valuated rather cheaply when we compare the Price/Earnings ratio to 27.38, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 13.07 indicates a correct valuation of PBH.
PBH's Price/Forward Earnings ratio is rather cheap when compared to the industry. PBH is cheaper than 83.25% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.86, PBH is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.78 | ||
| Fwd PE | 13.07 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PBH is valued cheaply inside the industry as 88.83% of the companies are valued more expensively.
89.85% of the companies in the same industry are more expensive than PBH, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.59 | ||
| EV/EBITDA | 10.51 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of PBH may justify a higher PE ratio.
PEG (NY)14.87
PEG (5Y)1.55
EPS Next 2Y3.24%
EPS Next 3Y2.71%
5. Dividend
5.1 Amount
No dividends for PBH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
63.1
-1 (-1.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners107.49%
Inst Owner Change-0.47%
Ins Owners1.26%
Ins Owner Change5.74%
Market Cap3.11B
Analysts78
Price Target85.27 (35.13%)
Short Float %2.92%
Short Ratio2.6
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.66%
Min EPS beat(2)-5.96%
Max EPS beat(2)0.64%
EPS beat(4)2
Avg EPS beat(4)-0.37%
Min EPS beat(4)-5.96%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-1.59%
EPS beat(12)7
Avg EPS beat(12)-47.18%
EPS beat(16)11
Avg EPS beat(16)-34.2%
Revenue beat(2)1
Avg Revenue beat(2)-1.94%
Min Revenue beat(2)-5.34%
Max Revenue beat(2)1.46%
Revenue beat(4)2
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-5.34%
Max Revenue beat(4)1.46%
Revenue beat(8)3
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.45%
PT rev (1m)-6.9%
PT rev (3m)-7.93%
EPS NQ rev (1m)-1.69%
EPS NQ rev (3m)-18.97%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.78 | ||
| Fwd PE | 13.07 | ||
| P/S | 2.77 | ||
| P/FCF | 11.59 | ||
| P/OCF | 11.26 | ||
| P/B | 1.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.51 |
EPS(TTM)4.58
EY7.26%
EPS(NY)4.83
Fwd EY7.65%
FCF(TTM)5.44
FCFY8.63%
OCF(TTM)5.6
OCFY8.88%
SpS22.76
BVpS37.71
TBVpS-19.66
PEG (NY)14.87
PEG (5Y)1.55
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.21% | ||
| ROE | 11.48% | ||
| ROCE | 10.5% | ||
| ROIC | 7.95% | ||
| ROICexc | 8.3% | ||
| ROICexgc | 73.5% | ||
| OM | 31.15% | ||
| PM (TTM) | 19.02% | ||
| GM | 56.13% | ||
| FCFM | 23.91% |
ROA(3y)3.39%
ROA(5y)4.11%
ROE(3y)6.22%
ROE(5y)8.76%
ROIC(3y)8.16%
ROIC(5y)7.67%
ROICexc(3y)8.33%
ROICexc(5y)7.8%
ROICexgc(3y)85.26%
ROICexgc(5y)93.76%
ROCE(3y)10.78%
ROCE(5y)10.14%
ROICexcg growth 3Y-14.1%
ROICexcg growth 5Y-7.82%
ROICexc growth 3Y5.03%
ROICexc growth 5Y3.52%
OM growth 3Y0.37%
OM growth 5Y-0.32%
PM growth 3Y-0.06%
PM growth 5Y5%
GM growth 3Y-0.79%
GM growth 5Y-0.88%
F-Score8
Asset Turnover0.33
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.55 | ||
| Debt/FCF | 3.79 | ||
| Debt/EBITDA | 2.67 | ||
| Cap/Depr | 26.62% | ||
| Cap/Sales | 0.71% | ||
| Interest Coverage | 7.65 | ||
| Cash Conversion | 72.82% | ||
| Profit Quality | 125.75% | ||
| Current Ratio | 4.38 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z | 2.63 |
F-Score8
WACC9.34%
ROIC/WACC0.85
Cap/Depr(3y)27.42%
Cap/Depr(5y)37.16%
Cap/Sales(3y)0.75%
Cap/Sales(5y)1.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.21%
EPS 3Y3.72%
EPS 5Y8.88%
EPS Q2Q%5.56%
EPS Next Y0.93%
EPS Next 2Y3.24%
EPS Next 3Y2.71%
EPS Next 5Y3.32%
Revenue 1Y (TTM)0.63%
Revenue growth 3Y1.54%
Revenue growth 5Y3.39%
Sales Q2Q%-6.59%
Revenue Next Year-2.1%
Revenue Next 2Y0.04%
Revenue Next 3Y0.52%
Revenue Next 5Y1.15%
EBIT growth 1Y5.97%
EBIT growth 3Y1.92%
EBIT growth 5Y3.06%
EBIT Next Year11.24%
EBIT Next 3Y3.43%
EBIT Next 5Y2.94%
FCF growth 1Y26.73%
FCF growth 3Y-0.94%
FCF growth 5Y4.02%
OCF growth 1Y25.6%
OCF growth 3Y-1.09%
OCF growth 5Y2.99%